RESULTS: 952,819 patients were reviewed for inclusion and 588,369 patients met the inclusion/exclusion criteria, of which 42,679 used myAir and 545,690 were in AirView-only. For the primary analysis population, there were 10,670 myAir patients and 21,340 AirView-only patients matched on propensity scores Baseline characteristics were similar between the two groups (age, gender, device type, device mode, therapy initiation AHI). Patients in both groups were effectively treated with PAP therapy over the 90 days (mean residual AHI of myAir 2.7 vs AirView-only 3.2). All adherence endpoints were statistically and clinically significant in favor of myAir. There was a significant improvement in the percent of patients that reached Medicare adherence within 90 days (myAir 87.5% vs. AirView-only 70.3%, p <0.0001), showing an improvement in adherence of 17%. Additional outcomes include: the percent of patients that achieved adherence within the first 30 days of use (myAir 79.6% vs. AirView-only 59.6%, p <0.0001), mean daily PAP usage (5.9 vs 4.9 hrs, p <0.0001), and the percent of patients with use ≥4 hours/day (83.6% vs 66.2%, p <0.0001).